Children with Type 1 diabetes can have their pizza and eat it, too, if they calculate their premeal insulin dose according to carbohydrate, fat, and protein intake rather than carbohydrate intake alone, researchers reported…. 

Real-time (RT) continuous glucose monitoring (CGM) can significantly improve daytime and nighttime glucose control, but only if patients use it properly and get the right support, according to a psychologist who studies barriers to successful implementation of the technology…. 

Conversion from exenatide to liraglutide is well tolerated and provides additional glycemic control and cardiometabolic benefits….

In patients with Type 2 diabetes, inhaled insulin before each meal, plus insulin glargine before bedtime, is just as effective at controlling blood sugar as conventional twice-daily premixed biaspart insulin therapy, according to new research…. 

Obese boys who engaged in regular aerobic or resistance exercise — without dietary changes — had significant improvements over 3 months in their total body fat, visceral adipose tissue concentrations, and insulin sensitivity than their more sluggish counterparts, according to the results of a randomized study….

In patients with Type 1 diabetes and poor glycemic control, the use of a sensor-augmented insulin pump significantly improved their A1c levels, compared with a regimen of multiple daily insulin injections, according to a new study…. 

From heart transplant material to cancer therapies, pigs have provided a host of opportunities for humans, Now pigs have come to the rescue once again — this time for diabetes….

Some patients with diabetes may not benefit from aggressive management of cardiovascular risk factors and some may even be harmed, according to a statistical model based on a government health survey.… 

One of the important announcements coming out of the American Diabetes Association’s 70th Scientific Sessions were the results of a little known NIH study titled, “The Healthy Study: Interventions to reduce early diabetes risk.” This may be a new model of how we can prevent our children from getting diabetes….

Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced the initiation of a confirmatory Phase 3 clinical trial to further evaluate otelixizumab in autoimmune new-onset Type 1 diabetes….